Mymetics reclaims innovative intra-nasal influenza vaccine

Epalinges, Switzerland, 4 October 2011

Mymetics Corporation, a pioneer in the development of vaccines that use the human mucosal system, the body’s first line of defense, to prevent transmission of infectious diseases, announced today that it has been able to regain its innovative intra-nasal influenza vaccine from Solvay.

Media Name Media Type Description Download
111004 Final Press release intra-nasal Flu PDF Download